Gregory D. Huhn, MD, an infectious disease specialist at the Ruth M. CORE Center in Chicago, and his colleagues reported Week 48 results from the EMERALD trial in subgroups based on age, gender and race. The phase 3, randomized trial was a non-inferiority trial of HIV patients whose virus was virologically suppressed on their current treatment. The study looked at the efficacy and safety of switching these patients to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF,
MAY 30, 2018